- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Biological
- Lead sponsor
- Nexcella Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Berkeley, California • Duarte, California • Los Angeles, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 400
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
- Interventions
- ACDN-01
- Drug
- Lead sponsor
- Ascidian Therapeutics, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 11
- States / cities
- San Francisco, California • Gainesville, Florida • Miami, Florida + 8 more
- Conditions
- HCC
- Interventions
- GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
- Biological · Drug · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Friedreich Ataxia, Cardiomyopathy, Secondary
- Interventions
- Low dose LX2006, Mid Dose LX2006, High Dose LX2006
- Genetic
- Lead sponsor
- Lexeo Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Rochester, Minnesota
- Conditions
- Choroideremia
- Interventions
- Injection of AAV2-REP1 (10e11 vg)
- Biological
- Lead sponsor
- Byron Lam
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Medullary Thyroid Cancer (MTC)
- Interventions
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- DMD-Associated Dilated Cardiomyopathy
- Interventions
- SRD-001
- Genetic
- Lead sponsor
- Sardocor Corp.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-003, KEYTRUDA®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
- Interventions
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
- Interventions
- Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colorectal Cancer
- Interventions
- cf-circRNA assay
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Choroideremia
- Interventions
- 4D-110
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Salt Lake City, Utah
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Parkinson's Disease
- Interventions
- Multiplex Sensitivity Encoding (MUSE)
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Influenza
- Interventions
- DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Hemophilia A
- Interventions
- AAV2/8-HLP-FVIII-V3
- Biological
- Lead sponsor
- University College, London
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 3
- States / cities
- Boise, Idaho • Lexington, Kentucky • Memphis, Tennessee
- Conditions
- Influenza, Influenza Immunization
- Interventions
- Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 20
- States / cities
- Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
- Interventions
- ET140203 T Cells
- Drug
- Lead sponsor
- Eureka Therapeutics Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 1 more
- Conditions
- Reading Problem
- Interventions
- Reading, Mindset, Reading Embedded with Mindset, Business as Usual
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Dallas, Texas
- Conditions
- Speech Sound Disorder
- Interventions
- Visual-acoustic biofeedback, Motor-based treatment
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 9 Years to 15 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Bloomfield, New Jersey • Syracuse, New York
- Conditions
- Motivation, Memory, Self-regulation
- Interventions
- Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sleep Disorder, Circadian Dysregulation
- Interventions
- Trans-C for sleep and circadian function + Memory Support
- Behavioral
- Lead sponsor
- University of California, Berkeley
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Moderna COVID-19 Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 1,923 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
- Conditions
- Ebola
- Interventions
- Ad26.ZEBOV, MVA-BN-Filo, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more